El.En (ELN) El.En.: la bella addormentata con oltre 60 milioni di "dote"... (1 Viewer)

paolonsky

Nuovo forumer
Se non li prendiamo di qua , li prendiamo di là ..

Cynosure, Inc. (NASDAQ: CYNO) a leader in laser- and light-based aesthetic treatments, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SculpSure™, the world's first hyperthermic laser treatment for non-invasive lipolysis of the flanks. Cynosure plans to introduce SculpSure through its U.S. direct sales force late in the second half of 2015.

Utilizing patented technology, SculpSure is a clinically proven and safe treatment designed to reduce fat non-invasively by disrupting subcutaneous fat cells. The versatile, hands-free device features a flexible applicator system to treat multiple anatomical areas of the body. SculpSure, which uses a 1060 nm laser, can treat an anatomical area in approximately 25 minutes. Patients are able to achieve desired results without downtime or surgery.

"SculpSure represents an entirely new approach to non-invasive lipolysis, one that is safe and highly effective in reducing adipose tissue and does so in significantly less time than other current treatments," said Cynosure Chairman and CEO Michael Davin. "We believe that the combination of these benefits enables us to offer practitioners the lowest total cost of ownership of any non-invasive lipolysis treatment on the market today, which in turn significantly enhances their return on investment."

Abstracts presented at the 2015 American Society for Laser Medicine and Surgery Annual Conference featured clinical data from approximately 100 subjects treated with SculpSure in multicenter studies at two U.S. sites. Researchers saw statistically significant reduction in adipose layer thickness, six and 12 weeks post-treatment. SculpSure is intended for individuals with a body mass index (BMI) of 30 or less. According to the World Health Organization, in 2014 approximately 1.3 billion adults 18 years and older worldwide were overweight.

"While SculpSure is our first non-invasive lipolysis treatment, the device leverages the expertise we have gained through the successful development and commercial launch of products including SmartLipo™ and Cellulaze™," Davin said. "It is a customer base and a treatment area we know extremely well. This clearance marks an important step in a broader marketing strategy that includes expanded treatment indications and new geographic markets. Currently, for example, we are pursuing FDA 510(k) clearance of SculpSure for non-invasive lipolysis of the abdomen, one of a number of potential catalysts we believe will help drive adoption of this technology."



Read more: Cynosure Receives FDA 510(k) Clearance for SculpSure - Cynosure, Inc. (NASDAQ:CYNO) | Benzinga
 

Spotti

.
paolonsky ha scritto:
Cynosure, Inc. (NASDAQ: CYNO) a leader in laser- and light-based aesthetic treatments, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SculpSure™, the world's first hyperthermic laser treatment for non-invasive lipolysis of the flanks. Cynosure plans to introduce SculpSure through its U.S. direct sales force late in the second half of 2015.

Utilizing patented technology, SculpSure is a clinically proven and safe treatment designed to reduce fat non-invasively by disrupting subcutaneous fat cells. The versatile, hands-free device features a flexible applicator system to treat multiple anatomical areas of the body. SculpSure, which uses a 1060 nm laser, can treat an anatomical area in approximately 25 minutes. Patients are able to achieve desired results without downtime or surgery.

"SculpSure represents an entirely new approach to non-invasive lipolysis, one that is safe and highly effective in reducing adipose tissue and does so in significantly less time than other current treatments," said Cynosure Chairman and CEO Michael Davin. "We believe that the combination of these benefits enables us to offer practitioners the lowest total cost of ownership of any non-invasive lipolysis treatment on the market today, which in turn significantly enhances their return on investment."

Abstracts presented at the 2015 American Society for Laser Medicine and Surgery Annual Conference featured clinical data from approximately 100 subjects treated with SculpSure in multicenter studies at two U.S. sites. Researchers saw statistically significant reduction in adipose layer thickness, six and 12 weeks post-treatment. SculpSure is intended for individuals with a body mass index (BMI) of 30 or less. According to the World Health Organization, in 2014 approximately 1.3 billion adults 18 years and older worldwide were overweight.

"While SculpSure is our first non-invasive lipolysis treatment, the device leverages the expertise we have gained through the successful development and commercial launch of products including SmartLipo™ and Cellulaze™," Davin said. "It is a customer base and a treatment area we know extremely well. This clearance marks an important step in a broader marketing strategy that includes expanded treatment indications and new geographic markets. Currently, for example, we are pursuing FDA 510(k) clearance of SculpSure for non-invasive lipolysis of the abdomen, one of a number of potential catalysts we believe will help drive adoption of this technology."



Read more: Cynosure Receives FDA 510(k) Clearance for SculpSure - Cynosure, Inc. (NASDAQ:CYNO) | Benzinga
Clicca per allargare...

Cynosure ha chiuso dopo la news a 37,99$... :rolleyes:

...la quota di El.En. corrisponde a 38 milioni di dollari (o quasi 35 milioni di euro)... :rolleyes:

...a questi livelli sarei molto felice se decidessero di passare alla cassa (anche se magari poi la dovessimo vedere ancora più in alto)! :ciao:
 

Spotti

.
b&t ha scritto:
Calma Amici di s-Ventura :)

Per fortuna che questo e' un fol dove non si sentono delle scemenze tipo.." ne parli male perché le vuoi prendere piu' in basso", come che si fosse in grado di gestire le quotazioni

Non esistono aziende perfette, anche il sottoscritto quando aveva detto tempo fa "EL.EN non integra, non crea sinergie come si dovrebbe" aveva fatto di un erba un fascio.

L'operazione Cyno di tanti anni fa e' stata straordinaria, io negli anni successivi non ero azionista, pero' a fronte di quella super operazione ve ne sono state alcune, di piccolo cabotaggio, di crescita partecipazione dal 65% al 80% che MrMojo ha ben descritto e che di fatto non hanno certo apportato vantaggi ai piccoli azionisti su un miglioramento della marginalita'.

A me il business che sta portando avanti EL.EN soddisfa, ma si puo' sempre migliorare
Clicca per allargare...

Pur non conoscendo in dettaglio le situazioni delle singole aziende componenti il gruppo El.En., prendo spunto dal post di B&T per provare a spezzare una lancia a favore del management relativamente ad alcune acquisizioni di quote di minoranza avvenute in passato e criticare da alcuni utenti del FOL (in particolare MrMojo) in quanto a loro avviso eccessivamente onerose e, potenzialmente, in conflitto di interesse o comunque poco trasparenti: nel momento in cui si acquista una società (sia nel caso di controllo che di quota di minoranza) non si può prescindere dalle prospettive future ed un prezzo anche apparentemente "salato" potrebbe essere del tutto giustificato dal fatto che la pipeline dei prodotti lascia intuire una crescita esponenziale della dimensione e della redditività futura... :rolleyes:

Effettivamente El.En. negli ultimi trimestri sta mostrando una crescita rilevante ed in crescita (tale dato è particolarmente sorprendente nell'ultimo quarter) e non è possibile escludere che tali risultati siano stati conseguiti anche da quelle aziende di cui si sono acquistate nel recente passato quote di minoranza (se non sbaglio la stessa Deka) a prezzi apparentemente elevati (ma ricordiamo che nel mercato i multipli normali sono ben diversi da quelli impliciti di El.En.) e dunque certe valutazioni potrebbero "con il senno del poi" dover essere riviste e le decisioni assunte dal management dimostrarsi forse addirittura lungimiranti! :bye:
 

franci63

Forumer storico
Spotti ha scritto:
Cynosure ha chiuso dopo la news a 37,99$... :rolleyes:

...la quota di El.En. corrisponde a 38 milioni di dollari (o quasi 35 milioni di euro)... :rolleyes:

...a questi livelli sarei molto felice se decidessero di passare alla cassa (anche se magari poi la dovessimo vedere ancora più in alto)! :ciao:
Clicca per allargare...

tranqui....aspettano che si ridimensioni un po':D...in 2 giorni - 6:-o
 

Spotti

.
Dite che il book in vendita è per caso un po' "farlocco"? :mumble:

EL.EN.: ELN.MI
27/05/15 - 12:21:30 Min/Max Open/Close Volume
37,5 € -0,33€ 37,4600 37,9700 3.287
-0,87% 37,9700 37,8300
# Q.Denaro P.Denaro
2 94 37,4400
1 74 37,4300
2 150 37,3900
1 50 37,3800
2 245 37,3100
P.Lettera Q.Lettera #
37,5000 106 2
37,6700 189 1
37,6800 189 1
37,7100 189 1
37,7200 189 1

:D:D:D
 

vincislato

Forumer attivo
Spotti ha scritto:
Dite che il book in vendita è per caso un po' "farlocco"? :mumble:

EL.EN.: ELN.MI
27/05/15 - 12:21:30 Min/Max Open/Close Volume
37,5 € -0,33€ 37,4600 37,9700 3.287
-0,87% 37,9700 37,8300
# Q.Denaro P.Denaro
2 94 37,4400
1 74 37,4300
2 150 37,3900
1 50 37,3800
2 245 37,3100
P.Lettera Q.Lettera #
37,5000 106 2
37,6700 189 1
37,6800 189 1
37,7100 189 1
37,7200 189 1

:D:D:D
Clicca per allargare...

;);););)
 

Spotti

.
Osservando anche oggi il book di El.En. in modalità push, sembra di vedere l'albero di Natale che si illumina ad intermittenza... :D:D:D
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 2 (members: 0, guests: 2)
Alto